ClinicalTrials.gg
RecruitingNCT07441889Updated Jun 12, 2026

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

A Phase 1/2 interventional study of HER2 FPBMC in Breast Cancer and Prostate Cancer, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by University of Virginia · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Breast Neoplasms by University of Virginia — 6 open to participants now, 7 under way, 2 of them phase 3. Breast Neoplasms · University of Virginia.

Planned enrollment
12th of 17
23 · median 45
Started
2026
with 2 others
Phase 1/2
2 of 18
1 open now
Registered
16th of 18
by date

Among the 18 studies in Breast Neoplasms by University of Virginia, this one is the 12th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 1/2, and was the 16th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 18 studies in Breast Neoplasms by University of Virginia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Breast Neoplasms by University of Virginia, or all of them as a file.
02

Study summary

The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostate cancer. Participants receive 5 weekly doses of CD33 FPBMC by intravenous infusion followed by 4 infusions every other week.

Read the detailed description

Once subjects are determined to be eligible, white blood cells (lymphocytes) are collected via leukapheresis procedure. The T cells in the mononuclear cells are coated with bispecific antibody to activate the T cells and the mononuclear cells are re-infused into the patients so the T cells can multiply and kill cancer cells. At least 72 hours after the leukapheresis procedure, study treatment will start. After 5 HER2 FPBMC infusions, participants will have another leukapheresis procedure. Before, throughout and following study treatment, research blood will be collected to better understand immune response. Disease status will be checked regularly during and after study treatment.

03

Conditions studied

  • Breast Cancer
  • Prostate Cancer

Keywords

  • FPBMC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Age ≥ 18 years at the time of signing informed consent
  4. Expected survival ≥ 3 months in the judgment of the investigator
  5. PS 0-1
  6. Adequate Organ Function per the following criteria (within 10 days of study registration):

    • Absolute lymphocyte count ≥ 400/mm3
    • ≥ 1000/mm3
    • ≥ 75,000/mm3
    • ≥ 9g/dL
    • Serum creatinine \< 2.0 mg/dL OR measured or calculated ≥ 50 ml/mm
    • Total ≤ mg/dL
    • (AST) and Alanine aminotransferase (ALT) \< 5.0 times normal
  7. Agreement to adhere to Lifestyle Considerations throughout study duration
  8. A diagnosis of either of the following:

    a. Prostate Cancer: i. Histological and/or cytological confirmation of prostate adenocarcinoma. ii. Participants must have progressive mCRPC at screening iii. Serum testosterone levels \<50 ng/dL during screening. iv. Must have progressed on at least one prior ARPI (abiraterone acetate, enzalutamide, apalutamide, or darolutamide).

    v. Participants must have ≥1 lesion that is present on baseline CT, MRI, or bone scan obtained ≤28 days prior to registration.

    b. Breast Cancer i. Histological and/or cytological confirmation of invasive breast cancer. ii. Participants must have previously treated metastatic breast cancer at screening. Metastatic breast cancer must be evaluable by 1.1 criteria.

iii. Must have progressed on at least two prior endocrine or targeted therapies or at least two lines of cytotoxic chemotherapy. If positive, then must have progressed on or been intolerant of at least one HER2 targeted therapy.

iv. Participants must have ≥1 metastatic lesion that is present on baseline CT, MRI, or bone scan obtained ≤28 days prior to registration.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy (must have negative pregnancy test within 7 days prior to study registration) or lactation
  2. History of a recent myocardial infarction (within one year) or a past myocardial infarction (more than one year prior to enrollment) who are actively requiring nitroglycerine more than once per week
  3. Inadequate cardiac function, as defined as any of the following:

    • Uncontrolled angina or severe ventricular arrhythmias
    • pericardial disease
    • History of myocardial infarction (MI) in the last year before registration
    • Class 3 or higher Congestive Heart Failure
  4. Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of therapy within 7 days prior to study registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  5. Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open or significant traumatic injury within 28 days prior to registration
  6. Active liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis
  7. Is positive or has evidence of active virus or active virus.
  8. Active bleeding or a pathological condition that is associated with a high risk of bleeding (therapeutic anticoagulation is allowed)
  9. Has an active infection requiring systemic therapy
  10. A serious uncontrolled medical disorder that in the opinion of the Investigator may be jeopardized by the treatment with protocol therapy
  11. Has a known history of active TB (Bacillus Tuberculosis)
  12. Has received a within 30 days of study registration.
  13. Treatment with any agent within 3 weeks prior to study registration
  14. Active second requiring systemic treatment. Exceptions include basal cell carcinoma of the skin, treated cervical cancer, and squamous cell carcinoma of the skin
  15. Has active disease that has required systemic treatment in the 2 years prior to registration (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
  17. Patient may be excluded if, in the opinion of the PI and investigator team, the patient is not capable of being compliant

Additional Exclusion Criteria for Patients with Prostate Cancer:

  1. Has small cell neuroendocrine carcinoma (pure or mixed) on prior or current histologic evaluation of primary or lesions
  2. Has an actionable BRCA1 or BRCA2 alteration, for which approved therapies are available, e.g., PARP inhibitors, unless these therapies are not appropriate for the participant as determined by the investigator or the participant refuses such therapy. Participants with one of these mutations and who have progressed on targeted therapy are eligible.

Additional Exclusion Criteria for Patients with Breast Cancer:

  1. Has an actionable BRCA1 or BRCA2 alteration, for which approved therapies are available, e.g., PARP inhibitors, unless these therapies are not appropriate for the participant as determined by the investigator or the participant refuses such therapy. Participants with one of these mutations and who have progressed on targeted therapy are eligible.
  2. Participants in visceral crisis at risk of immediately life-threatening complications in the short term, including participants with massive uncontrolled effusions (pleural, pericardial, and peritoneal), pulmonary lymphangitis, or liver involvement > 50%.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (estimated)

Study arms

  • Experimental
    HER2 FPBMC

    Five weekly infusions of HER2 fresh peripheral blood mononuclear cells (FPBMC) followed by 4 HER2 FPBMC infusions every other week

    Drug: HER2 FPBMC

Interventions

  • DrugHER2 FPBMC

    Participants will receive 5 weekly infusions of HER2 FPBMC infusions followed by 4 additional infusions every other week.

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicities (DLTs)

    DLTs in the dose escalation phase

    Time frame: During the first 5 infusions (5 weeks) for each participant

Secondary outcomes

  1. Total cells collected

    Total cells collected for each participant (for creation of cell product) at each timepoint for collection

    Time frame: For each participant, prior to starting study treatment (induction) and then prior to boost/retreatment infusions (about 9-10 weeks later)

  2. Overall response rate

    Percent of participants that have a response (complete or partial) to study treatment

    Time frame: During and immediately after study treatment for each participant (a maximum of ~20 weeks)

  3. Progression free survival

    Time from start of study treatment through first disease progression afterward (for each participant)

    Time frame: For up to 3 years after last infusion for each participant (about 3 1/2 years)

  4. Overall survival

    Time from start of study treatment through death from any cause (for each participant)

    Time frame: For up to 3 years after last infusion for each participant (about 3 1/2 years)

  5. Adverse events

    As described using CTCAE v5.0

    Time frame: During and through ~30 days after end of study treatment (maximum of about 24 weeks)

  6. Development of specific cytotoxicity by PBMCs (of participants) as measured by cytotoxicity or IFN-γ EliSpots responses

    To breast and prostate cancer cell lines, respectively

    Time frame: Multiple timepoints during and through ~30 days after end of study treatment (maximum of about 24 weeks)

  7. Serum antibodies to breast or prostate cancer cell lines and ELISA for IgG-specific antibody to HER2 and EGFR2

    Time frame: Multiple timepoints during and through ~30 days after end of study treatment (maximum of about 24 weeks)

  8. Survival kinetics of HER2 FPBMCs after a single infusion

    Time frame: Multiple timepoints before and after the first 5 infusions (week 5)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Oct 2029, 40 months later.

Of 167 non-industry phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 95. This study's planned 40 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Mar 2, 2026
StartEst.
Jun 2026
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2032
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07441889
Responsible party
Paul Viscuse (Assistant Professor, University of Virginia) — Principal investigator
First posted
Mar 2, 2026
Start date
Jun 2026 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Oct 2032 (estimated)
Last update
Jun 12, 2026

Study contacts

Ashley Lamont
Contact
ZWZ6JM@uvahealth.org
(434) 243-6377
Laura Livingston
Contact
LL9TE@uvahealth.org
434-882-5578
Paul Viscuse, MD
principal investigator · University of Virginia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion